Effect of Psychoactive Drugs on Behavior Induced by 2-Phenylethylamine in Rats

  • R. Ortmann
  • M. Schaub
  • P. C. Waldmeier

Abstract

2-Phenylethylamine (PEA) combines 2 features which are important for the behavioral pharmacologist interested in the characterization of monoamine oxidase (MAO) inhibitors in rats: It is degraded rather specifically by the B-form of MAO (Yang and Neff 1974) and produces stereotyped behavior in rodents. Several authors have shown that the intensity of stereotyped behavior is greatly increased by inhibitors of the B-type of MAO, while MAO-A inhibitors were much less active (Braestrup et. al 1975, 1978; Moja et al. 1976). We tried to establish a behavioral test system in vivo which would allow us to determine the inhibitory specificity of a given compound for the A- or B-type of MAO. The potency of various MAO-inhibitors to potentiate stereotyped behavior induced by PEA was compared with their effect on L-5-hydroxytryptophan (L-HTP)-induced excitation in rats. The latter test has been shown to be specific for MAO-A inhibitors (Ortmann et al. 1980). In addition we compared the behavioral effects of the test compounds in the PEA test with their ability to increase PEA levels of rat brain and to inhibit MAO in an ex vivo assay.

Keywords

Reserpine animaLs Tryptamine Padding MOCLOBEMIDE 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Braestrup C., Andersen H. and Randrup A. (1975) The monoamine oxidase inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur. J. Pharmacol. 34,181–187PubMedCrossRefGoogle Scholar
  2. Braestrup C. and Randrup A. (1978) Stereotyped behavior in rats induced by phenylethylamine, dependence on dopamine and noradrenaline, and possible relation to psychoses? in Noncatecholic Phenylethylamines, eds. A. Mosnaim, M.E. Wolf. Marcel Dekker pp 245–269Google Scholar
  3. Dourish C.T. (1981) Behavioural effects of acute and chronic 6-phenylethylamine administration in the rat: Evidence for the involvement of 5-HT. NeuropharmacoI. 20, 1067–1072CrossRefGoogle Scholar
  4. Fischer R.A. (1958) Statistical methods for research workers. 13th edition, Oliver and Boyd Ltd, Edinburgh, p 96Google Scholar
  5. Fuxe K., Gobecker H. and Jonssen J. (1967) The effect of β-phenylethylamine on central and peripheral monoamine-containing neurones. Eur. J. Pharmacol. 2, 202–207PubMedCrossRefGoogle Scholar
  6. Lauber J. and Waldmeier P.C. (1984) Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS. J Neural Tansm. 60 247–264CrossRefGoogle Scholar
  7. Moja E.A., Stoff D.M., Gillin J.C. and Wyatt R.J. (1976) Dose-response effects of β-phenylethylamine on stereotyped behavior in pargyIine-pretreated rats. Biol. Psychiatry 11 731–742PubMedGoogle Scholar
  8. Moretti A., Caccia C., Calderini G., Menozzi M. and Amico A. (1981) Studies on the mechanism of action of caroxazone, a new antidepressant drug. Biochem Pharmacol 30 2728–2731PubMedCrossRefGoogle Scholar
  9. Ortmann, R., Waldmeier, P.C., Radeke, E., Felner, A. and Delini-Stula, A (1980) The effects of 5-HT uptake-and MAO-inhibitors on L-5-HTP-induced excitation in rats. Naunyn-Schmiedeberg’s Arch. Pharmacol. 311 185–192CrossRefGoogle Scholar
  10. Ortmann, R., Martin, S. and WaIdmeier, P.C. (1981) Supersensitivity to L-5-HTP after hydroxy-tryptamine injections in desmethimipramine-and nomi fensine-pretreated rats: Behavioral evidence for postsynaptic supersensitivity. Psychopharmacol. 74109–114CrossRefGoogle Scholar
  11. Ortmann R., Schaub M., Felner A., Lauber J., Christen P. and Waldmeier P.C. (1984a) Phenyleth amine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacol. 84, 22–27CrossRefGoogle Scholar
  12. Ortmann R. (1984b) The 5-HT syndrome in rats as tool for the screening of psychoactive drugs. Drug Dev. Res. 4 593–606CrossRefGoogle Scholar
  13. Sloviter R.S., Connor J.D., Drust E.G. (1980) Serotonergic properties of ß-phenylethylamine in rats. Neuropharmac 19 1071–1074CrossRefGoogle Scholar
  14. Strolin-Benedetti M. and Dow J.(1983) A MAO-B inhibitor, MD 780236, metabolized essentially by the A form of the enzyme in the rat. J. Pharm. Pharmacol 35 238–245PubMedCrossRefGoogle Scholar
  15. Wdmeier, P.C., Baumann, P.A., Maftre, L. (1979) CGP 6085 A a new, specific, inhibitor of serotonin uptake: Neurochemical characterization and comparison with other serotonin-uptake blockers. J. Pharm. Exp. Therap. 211,42–49Google Scholar
  16. Waldmeier, P.C., Baumann, P.A.(1983) Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain. Naunyn-Schmiedeb. Arch. Pharmacol. 324,20–26CrossRefGoogle Scholar
  17. Yang H.-Y.T. and Neff N.H. (1974) The Monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J. Pharm. Exp. Therap. 189 733–740Google Scholar

Copyright information

© The Humana Press Inc. 1985

Authors and Affiliations

  • R. Ortmann
    • 1
  • M. Schaub
    • 1
  • P. C. Waldmeier
    • 1
  1. 1.Research Department, Pharmaceuticals DivisionCIBA-GEIGY Ltd.BaselSwitzerland

Personalised recommendations